Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of Black Diamond Therapeutics's BDTX-1535?
BDTX-1535 is a small molecule commercialized by Black Diamond Therapeutics, with a leading Phase II program in Non-Small Cell Lung...
BDTX-1535 by Black Diamond Therapeutics for Recurrent Glioblastoma Multiforme (GBM): Likelihood of Approval
BDTX-1535 is under clinical development by Black Diamond Therapeutics and currently in Phase II for Recurrent Glioblastoma Multiforme (GBM). According...
BDTX-1535 by Black Diamond Therapeutics for Non-Small Cell Lung Cancer: Likelihood of Approval
BDTX-1535 is under clinical development by Black Diamond Therapeutics and currently in Phase II for Non-Small Cell Lung Cancer. According...
BDTX-1535 by Black Diamond Therapeutics for High-Grade Glioma: Likelihood of Approval
BDTX-1535 is under clinical development by Black Diamond Therapeutics and currently in Phase I for High-Grade Glioma. According to GlobalData,...
Risk adjusted net present value: What is the current valuation of Black Diamond Therapeutics's BDTX-1535?
BDTX-1535 is a small molecule commercialized by Black Diamond Therapeutics, with a leading Phase II program in Non-Small Cell Lung...